The 2024 Patient Partnership Index is now closed for entries.

The Patient Partnership Index is a ground-breaking initiative from specialist health communications agency OVID Health.

The inaugural Patient Partnership Index was launched in May 2020, offering pharmaceutical and biotech companies an opportunity to showcase, benchmark and evaluate the quality of their partnerships with patient groups.

Results of the 2024 Patient Partnership Index will be announced in due course. If you would like to be kept up to date about the index, please register your interest below.



This year the Index has been endorsed by the Association of the British Pharmaceutical Industry, the UK trade organisation for over 120 companies producing prescription medicines, and by the Healthcare Communications Association. 

“The PPI is a fantastic opportunity to showcase the best partnerships between the life sciences sector and patient groups from around the world, offering inspiration to others and showcasing the most creative and inspiring work.  As a professional body that upholds the highest standards within our industry, the APBI fully endorses the PPI and encourages companies to enter the initiative to celebrate and share best practice in partnerships.”

Colette Goldrick
Executive Director Corporate Affairs & Strategy, ABPI

The PPI is a great initiative offering companies big and small the opportunity to showcase the work they are doing to build trusted and lasting relationships with patient organisations. This type of work is so important in helping us to understand what matters most to patients and their families.

“As a professional association that seeks to unite and champion all those in healthcare communications, we are thrilled to be endorsing the PPI for the second year. We really encourage companies to enter, so we can celebrate and share best practice in partnerships.”

HCA logo

Mike Dixon
CEO, Healthcare Communications Association

The Index evaluates the highest standards, based on best practice, of partnerships in communications, advocacy, market access and uptake, clinical trials and R&D between pharmaceutical, biotech and patient communities. The aim is to celebrate as many partnerships that meet the mark as possible so we can continue to raise the bar across the industry.

Each company or patient group can submit up to three entries for in-market, regional or global projects. This includes patient advocacy, communications, public affairs, medical affairs, clinical trials and R&D partnerships. There are no costs involved – entering the Index is completely free for everyone.

In return for submitting entries to the Index, entrants are recognized by industry and patient organisation peers, for their commitment to putting patients at the heart of their work.

“Working in partnership is critical to enable transformative care for people with rare diseases, so we were delighted to be recognized for our partnership working in Immune Thrombocytopenia. The PPI is a great opportunity to benchmark our practices against the best the sector has to offer and provides impetus to continue to progress meaningful collaboration with the patient community.”

Sharon Hall, UK General Manager, Sobi, 2023 SILVER Standard entrant  

All entrants have the opportunity to profile their involvement with the Index through their own external and internal channels, and awards for GOLD, SILVER and FINALIST standard entries are announced by OVID Health to celebrate those companies who both demonstrate and lead best practice in patient partnerships.

If you have a project which you think showcases the best of partnership working between industry and patients, register your interest to be updated regarding the Patient Partnership Index.